Based on 3 Wall Street analysts offering 12 month price targets for Ovid Therapeutics in the last 3 months. The average price target is €7.03 with a high forecast of €7.50 and a low forecast of €6.56. The average price target represents a 139.07% change from the last price of €2.94.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","8":"€8","2.75":"€2.75","4.5":"€4.5","6.25":"€6.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.4972,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">€7.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.028625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">€7.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.56005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">€6.56</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.75,4.5,6.25,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.8,3.1613230769230767,3.5226461538461535,3.883969230769231,4.245292307692308,4.606615384615385,4.967938461538462,5.329261538461539,5.690584615384616,6.051907692307692,6.413230769230769,6.774553846153847,7.135876923076924,{"y":7.4972,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.8,3.125278846153846,3.450557692307692,3.7758365384615384,4.101115384615385,4.4263942307692306,4.751673076923077,5.076951923076923,5.402230769230769,5.727509615384616,6.052788461538461,6.378067307692308,6.703346153846153,{"y":7.028625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.8,3.089234615384615,3.378469230769231,3.667703846153846,3.9569384615384617,4.2461730769230766,4.535407692307692,4.824642307692308,5.113876923076923,5.4031115384615385,5.692346153846154,5.981580769230769,6.270815384615385,{"y":6.56005,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.6,"date":1681430400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.02,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.7,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€7.50

Average Price Target€7.03

Lowest Price Target€6.56

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Wedbush

xxxxxxxxxxxxx

Initiated

04/04/24

xxxxxxxxxxxxxxxxxx

Ladenburg Thalmann & Co.

xxxxxxxxxxxxx

Reiterated

03/12/24

xxxxxxxxxxxxxxxxxx

TD Cowen

xxxxxxxxxxxxx

Assigned

03/11/24

Thomas Shrader

BTIG

€10.31

Buy

250.63%

Upside

Initiated

12/21/23

Ovid Therapeutics initiated with a Buy at BTIGOvid Therapeutics initiated with a Buy at BTIG

Yigal Nochomovitz

Citi

€3.75

Hold

27.50%

Upside

Reiterated

12/04/23

Sean Kim PhD

JonesTrading

€5.62

Buy

91.26%

Upside

Reiterated

11/03/23

Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (NASDAQ: PSTV), Beyond Air (NASDAQ: XAIR) and Ovid Therapeutics (NASDAQ: OVID)

Francois Brisebois

Oppenheimer

€7.50

Buy

155.01%

Upside

Reiterated

10/18/23

Oppenheimer Sticks to Its Buy Rating for Ovid Therapeutics (OVID)

Sean Kim

RBC Capital

€5.62

Buy

91.26%

Upside

Initiated

06/13/23

Ovid Therapeutics (OVID) Has a New Rating from JonesTrading - TipRanks.comIn a report released today, Sean Kim PhD from JonesTrading initiated coverage with a Buy rating on Ovid Therapeutics ( OVID Research Report) and a price target of $6.00 . The companys shares closed today at $3.89.

Best Analysts Covering Ovid Therapeutics

Which Analyst Should I Follow If I Want to Buy DE:1OT and Sell After:

1 Month

Michael HigginsLadenburg Thalmann & Co.

Success Rate

14/31 ratings generated profit

Average Return

+1.65%

reiterated a buy rating last month

Copying Michael Higgins's trades and holding each position for 1 Month would result in 45.16% of your transactions generating a profit, with an average return of +1.65% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Ritu BaralTD Cowen

Success Rate

8/12 ratings generated profit

Average Return

+21.63%

assigned a buy rating last month

Copying Ritu Baral's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +21.63% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Ritu BaralTD Cowen

Success Rate

8/12 ratings generated profit

Average Return

+69.63%

assigned a buy rating last month

Copying Ritu Baral's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +69.63% per trade.

2 Years

Ritu BaralTD Cowen

Success Rate

9/12 ratings generated profit

Average Return

+42.63%

assigned a buy rating last month

Copying Ritu Baral's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +42.63% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1OT Analyst Recommendation Trends

Rating

Oct 23

Nov 23

Dec 23

Mar 24

Apr 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1OT has received 4 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 1OT average Analyst price target in the past 3 months is €7.03.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

1OT Financial Forecast

1OT Earnings Forecast

Next quarter’s earnings estimate for 1OT is -€0.21 with a range of -€0.25 to -€0.16. The previous quarter’s EPS was -€0.21. 1OT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 60.78% of the time in the same period. In the last calendar year 1OT has Underperformed its overall industry.

1OT Sales Forecast

Next quarter’s sales forecast for 1OT is €49.92K with a range of €0.00 to €157.30K. The previous quarter’s sales results were €133.34K. 1OT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 61.54% of the time in the same period. In the last calendar year 1OT has Outperformed its overall industry.

1OT Stock Forecast FAQ

What is DE:1OT’s average 12-month price target, according to analysts?

Based on analyst ratings, Ovid Therapeutics Inc’s 12-month average price target is €7.03.

What is DE:1OT’s upside potential, based on the analysts’ average price target?

Ovid Therapeutics Inc has 139.07% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Ovid Therapeutics Inc a Buy, Sell or Hold?

Ovid Therapeutics Inc has a conensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ovid Therapeutics Inc’s share price target?

The average share price target for Ovid Therapeutics Inc is €7.03. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €7.50 ,and the lowest forecast is €6.56. The average share price target represents 139.07% Increase from the current price of €2.94.

What do analysts say about Ovid Therapeutics Inc?

Ovid Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Ovid Therapeutics Inc?

To buy shares of DE:1OT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ovid Therapeutics (1OT) Stock Forecast & Price Target

1OT Analyst Ratings

1OT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ovid Therapeutics

1OT Analyst Recommendation Trends

1OT Financial Forecast

1OT Earnings Forecast

1OT Sales Forecast

1OT Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts